Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Passiglia

Showing results (61-70 of 127) with videos related to

Pageof 13
Sort By:
Cancers|June 2, 2021
Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-MutationsPaolo Bironzo, Maria Lucia Reale, Tessa Sperone, et al.
Frontiers in Immunology|May 25, 2026
A blood-based immune-suppressive index stratifies immunotherapy outcomes in advanced NSCLCLuca Lalli, Veronica Huber, Agata Cova, et al.
JCO Oncology Practice|July 6, 2021
Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 WavesAnnapaola Mariniello, Paolo Bironzo, Chiara Pisano, et al.
Cancers|March 14, 2026
Long-Term Oncological Outcomes of Minimally Invasive Surgery in Non-Small Cell Lung Cancer: An Updated ReviewMarco Donatello Delcuratolo, Michele Piazzolla, Doroty Sampietro, et al.
Therapeutic Advances in Medical Oncology|April 26, 2019
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patientsFrancesco Passiglia, Antonio Galvano, Marta Castiglia, et al.
Targeted Oncology|January 28, 2018
Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor ProgressionMarzia Pucci, Pablo Reclusa Asiáin, Elena Duréndez Sáez, et al.
Current Drug Targets|December 17, 2014
The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target?Francesco Passiglia, Nele Van Der Steen, Luis Raez, et al.
Therapeutic Advances in Medical Oncology|September 20, 2019
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysisAntonio Galvano, Simona Taverna, Giuseppe Badalamenti, et al.
Translational Lung Cancer Research|December 15, 2022
Treatment response and safety of immunotherapy for advanced non-small cell lung cancer with comorbid chronic obstructive pulmonary disease: a retrospective cohort studyKening Zhang, Chengzhi Zhou, Jiabo Gao, et al.
Future Oncology (London, England)|July 7, 2026
Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC)Francesco Passiglia, Eugenia Priedane, Silvy Mardiguian, et al.
Pageof 13

Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
Cancers|June 2, 2021
Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-MutationsPaolo Bironzo, Maria Lucia Reale, Tessa Sperone, et al.
Frontiers in Immunology|May 25, 2026
A blood-based immune-suppressive index stratifies immunotherapy outcomes in advanced NSCLCLuca Lalli, Veronica Huber, Agata Cova, et al.
JCO Oncology Practice|July 6, 2021
Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 WavesAnnapaola Mariniello, Paolo Bironzo, Chiara Pisano, et al.
Cancers|March 14, 2026
Long-Term Oncological Outcomes of Minimally Invasive Surgery in Non-Small Cell Lung Cancer: An Updated ReviewMarco Donatello Delcuratolo, Michele Piazzolla, Doroty Sampietro, et al.
Therapeutic Advances in Medical Oncology|April 26, 2019
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patientsFrancesco Passiglia, Antonio Galvano, Marta Castiglia, et al.
Targeted Oncology|January 28, 2018
Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor ProgressionMarzia Pucci, Pablo Reclusa Asiáin, Elena Duréndez Sáez, et al.
Current Drug Targets|December 17, 2014
The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target?Francesco Passiglia, Nele Van Der Steen, Luis Raez, et al.
Therapeutic Advances in Medical Oncology|September 20, 2019
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysisAntonio Galvano, Simona Taverna, Giuseppe Badalamenti, et al.
Translational Lung Cancer Research|December 15, 2022
Treatment response and safety of immunotherapy for advanced non-small cell lung cancer with comorbid chronic obstructive pulmonary disease: a retrospective cohort studyKening Zhang, Chengzhi Zhou, Jiabo Gao, et al.
Future Oncology (London, England)|July 7, 2026
Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC)Francesco Passiglia, Eugenia Priedane, Silvy Mardiguian, et al.
Pageof 13